JD Health International, Inc. (6618) AI Stock Analysis

• Market Cap: HK$157.33B
• Dividend Yield: N/A
• Average Volume (3M): 7.60M
• Price to Earnings (P/E): 30.1
• Beta (1Y): 1.46
• Revenue Growth: 18.56%
• EPS Growth: 79.54%
• Country: HK
• Employees: 3,564
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 1.06
• Shares Outstanding: 3,210,775,100
• 10 Day Avg. Volume: 6,883,323
• 30 Day Avg. Volume: 7,596,953
• PEG Ratio: 1.20
• Price to Book (P/B): 2.62
• Price to Sales (P/S): 2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$71.80
• Price Target Upside: 19.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 1.85
• Revenue Forecast (FY): HK$87.28B

• Rating: 72 Outperform
• Price Target: HK$54.00 ▼(-10.45% Downside)
• Action: Reiterated Date: 03/08/26
• Date: Action: Reiterated 03/08/26

The score is driven primarily by strong financial position and improving profitability, reinforced by a positive earnings call with robust growth and margin expansion. Offsetting these strengths, technical indicators are notably bearish and free-cash-flow volatility raises near-term cash-conversion risk; valuation appears reasonable based on the provided P/E.

Positive Factors

Very strong balance sheet and low leverage

Extremely low leverage and a growing equity base provide durable financial flexibility to fund R&D, pharmacy rollout and AI investments without forcing dilutive equity or heavy debt. This conservatism reduces bankruptcy risk and supports multi-year strategic optionality amid industry competition.

Sustained revenue growth with margin expansion

Double-digit revenue growth coupled with expanding gross margins indicates the business is achieving operational leverage and improving unit economics. Over 2–6 months this supports durable earnings improvement, giving management room to reinvest in growth while protecting profitability.

Strong operating cash generation and large engaged user base

Healthy operating cash flow funds ongoing investment without reliance on external financing, while a large, growing user base and high AI engagement create durable monetization optionality across services, insurance and on-demand retail as commercialization pathways mature.

Negative Factors

Free-cash-flow volatility and recent swing to zero FCF

A sharp swing in free cash flow to zero signals that investments or working-capital shifts materially alter cash conversion. Over the medium term this raises funding and capital-allocation risk: planned expansion or margin targets may require higher cash conversion to be sustainably financed.

High revenue concentration in direct-sales channel

With ~83% of revenue from direct sales the company is exposed to supplier, category and channel-specific shocks. Limited diversification magnifies competitive or regulatory risks in core categories and could force margin-reducing tactics to defend market share over the next several quarters.

AI monetization remains uncertain despite high engagement

High engagement metrics do not guarantee revenue; converting AI and doctor-facing products into repeatable enterprise or consumer revenue will require sustained R&D, sales and integration effort. If monetization lags, expected margin and service-revenue upside may underdeliver.

JD Health International, Inc. Business Overview & Revenue Model

Company Description

JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.

How the Company Makes Money

JD Health generates revenue through multiple streams. The primary revenue sources include online pharmaceutical sales, where the company earns margins from selling prescription and over-the-counter medications. Additionally, JD Health provides telehealth services, charging fees for virtual consultations with healthcare professionals. The company also offers health management and wellness services, with subscription models for ongoing care and monitoring. Significant partnerships with pharmaceutical companies and health institutions enhance its product offerings and expand its reach, while leveraging JD.com's vast logistics and e-commerce infrastructure further supports its revenue growth.

JD Health International, Inc. Financial Statement Overview

Summary

Strong balance sheet strength (minimal leverage) and improved profitability support a high score, but cash-flow quality is mixed: operating cash flow is strong while free cash flow showed sharp volatility (reported as zero in 2025), creating uncertainty around cash conversion.

Income Statement

Revenue has grown steadily over 2023–2025 (2025 up ~9.9% vs. 2024), and profitability has improved meaningfully from earlier losses (2020–2021) to solid profits in 2023–2025. Margins also strengthened in 2025 versus 2024 (higher gross and operating profitability), supporting better earnings quality. The main offset is some historical volatility—large losses earlier in the period and uneven operating profitability in the mid-years—suggesting the business has improved but is not yet a long-cycle “steady compounder.”

Balance Sheet

The balance sheet is very strong with extremely low leverage (debt-to-equity around ~0.5%–1.1% in 2021–2025) alongside a growing equity base. Returns on equity have improved with the turn to profitability (mid-to-high single digits in 2024–2025), while total assets have expanded over time. The key weakness is that returns are decent but not exceptional yet, implying the company is still building toward higher capital efficiency despite the conservative balance sheet.

Cash Flow

Operating cash flow is consistently positive across the period and rose sharply in 2025, which is a clear strength. However, free cash flow weakened materially in the latest year: 2024 showed strong free cash flow roughly in line with net income, while 2025 free cash flow is reported at zero (with -100% growth), indicating a significant swing likely driven by higher investment or working-capital needs. Overall cash generation looks healthy at the operating line, but the latest free-cash-flow volatility raises near-term quality and sustainability questions.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	71.54B	58.16B	53.53B	46.74B	30.68B
Gross Profit	17.73B	13.31B	11.87B	9.89B	7.20B
EBITDA	3.97B	1.31B	2.93B	-60.93M	-1.37B
Net Income	5.24B	4.16B	2.14B	380.11M	-1.07B
Balance Sheet
Total Assets	81.62B	71.27B	64.29B	61.28B	48.00B
Cash, Cash Equivalents and Short-Term Investments	47.00B	51.24B	41.22B	47.67B	41.99B
Total Debt	636.29M	258.39M	214.75M	199.41M	201.27M
Total Liabilities	21.52B	16.03B	14.92B	16.49B	8.15B
Stockholders Equity	60.10B	55.23B	49.36B	44.78B	39.85B
Cash Flow
Free Cash Flow	0.00	4.29B	4.54B	5.86B	2.93B
Operating Cash Flow	9.94B	4.33B	4.60B	5.91B	3.43B
Investing Cash Flow	-575.36M	3.15B	-8.02B	-4.24B	-17.75B
Financing Cash Flow	-77.10M	-45.61M	-117.20M	-925.45M	-163.65M

JD Health International, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 60.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Negative. The current price of 60.3 is above the 20-day moving average (MA) of 54.83, above the 50-day MA of 59.59, and above the 200-day MA of 56.91, indicating a bearish trend. The MACD of -3.18 indicates Positive momentum. The RSI at 33.24 is Neutral, neither overbought nor oversold. The STOCH value of 40.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6618.

JD Health International, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6618	72 Outperform	HK$157.33B	30.12	9.03%	―	18.56%	79.54%
3689	71 Outperform	HK$668.79M	3.30	5.29%	9.14%	0.47%	50.46%
1526	66 Neutral	HK$1.34B	14.78	20.47%	4.37%	-3.56%	-17.45%
2273	66 Neutral	HK$6.21B	12.63	14.86%	2.61%	16.41%	32.97%
6078	62 Neutral	HK$7.26B	17.43	4.98%	―	-13.92%	-36.32%
1951	55 Neutral	HK$6.09B	-1.79	-9.73%	2.38%	-8.56%	-403.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JD Health International, Inc. Corporate Events

JD Health Delivers Record 2025 Profit on AI-Driven Healthcare Expansion

JD Health reported strong audited results for 2025, with revenue rising 26.3% to RMB73.4 billion and gross profit climbing 36.7%, supported by its AI-enabled, full-scenario healthcare services ecosystem and omnichannel supply chain. Non-IFRS profit increased 36.3% to RMB6.5 billion, lifting the non-IFRS profit margin to 8.9%, while annual active users reached 217.7 million, marking four consecutive quarters of 20%-plus revenue growth and the highest full-year profit margin since inception.

The company deepened its role as an online launch platform for innovative medicines, introducing over 100 new drugs in 2025 and expanding a closed-loop model that integrates online consultation, pharmaceutical fulfillment and follow-up services. It also accelerated growth in health supplements and medical devices, scaling high-potential nutrition categories, collaborating on co-branded continuous glucose monitoring products and building an integrated intelligent health management framework, reinforcing its industry position and partnerships with pharmaceutical and device makers.

The most recent analyst rating on (HK:6618) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Sets March 5, 2026 Board Meeting to Approve 2025 Results and Mull Dividend

JD Health International Inc. has scheduled a board meeting for March 5, 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025, and to consider whether to recommend a final dividend. The outcome of this meeting will shape the company’s capital return decisions and provide investors with an updated view of its financial performance and strategic progress.

Management will also host a conference call on the same day at 5:00 pm Beijing/Hong Kong time to discuss the 2025 financial results with analysts and investors. The call underscores the company’s effort to maintain active communication with the market and may offer additional insight into operating trends and its positioning within the competitive digital healthcare sector.

The most recent analyst rating on (HK:6618) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Grants 536,489 Share Awards to Employees Under Post-IPO Scheme

JD Health International Inc. has granted 536,489 share awards, equivalent to about 0.02% of its issued share capital as of the grant date, to employees of the group (excluding directors and senior management) under its post-IPO share award scheme, with no consideration payable by the grantees. The awards, priced with reference to HK$55.50 per share, will vest in tranches over periods ranging from 0.25 to 4 years and are governed by a strict clawback framework that allows the company to forfeit or cancel unvested and vested shares, and recover related proceeds, in cases such as termination for cause, criminal offences involving integrity or honesty, misconduct damaging the group, or in connection with financial restatements, reinforcing JD Health’s long-term incentive structure and risk management over employee compensation.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$70.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health International Approves Key Agreements at Extraordinary General Meeting

JD Health International, Inc. announced the successful approval of all proposed resolutions during its Extraordinary General Meeting held on December 8, 2025. The resolutions include agreements with JD.com for technology and traffic support services and the provision of healthcare products and services, which are expected to strengthen the company’s operational capabilities and market position.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$70.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.